- Home
- GWRS vs CERS Comparison
GWRS vs CERS Comparison
Compare GWRS & CERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GWRS
- CERS
- Stock Information
- Founded
- GWRS 2003
- CERS 1991
- Country
- GWRS United States
- CERS United States
- Employees
- GWRS N/A
- CERS N/A
- Industry
- GWRS Water Supply
- CERS EDP Services
- Sector
- GWRS Utilities
- CERS Technology
- Exchange
- GWRS Nasdaq
- CERS Nasdaq
- Market Cap
- GWRS 272.5M
- CERS 276.0M
- IPO Year
- GWRS 2010
- CERS 1997
- Fundamental
- Price
- GWRS $10.02
- CERS $1.75
- Analyst Decision
- GWRS
- CERS Buy
- Analyst Count
- GWRS 0
- CERS 1
- Target Price
- GWRS N/A
- CERS $4.00
- AVG Volume (30 Days)
- GWRS 68.9K
- CERS 1.2M
- Earning Date
- GWRS 11-12-2025
- CERS 11-06-2025
- Dividend Yield
- GWRS 3.04%
- CERS N/A
- EPS Growth
- GWRS N/A
- CERS N/A
- EPS
- GWRS 0.22
- CERS N/A
- Revenue
- GWRS $54,270,000.00
- CERS $199,191,000.00
- Revenue This Year
- GWRS $8.40
- CERS $19.07
- Revenue Next Year
- GWRS $8.39
- CERS $12.03
- P/E Ratio
- GWRS $45.87
- CERS N/A
- Revenue Growth
- GWRS 4.33
- CERS 13.03
- 52 Week Low
- GWRS $9.27
- CERS $1.12
- 52 Week High
- GWRS $13.98
- CERS $2.24
- Technical
- Relative Strength Index (RSI)
- GWRS 44.43
- CERS 62.48
- Support Level
- GWRS $10.00
- CERS $1.38
- Resistance Level
- GWRS $10.50
- CERS $1.54
- Average True Range (ATR)
- GWRS 0.24
- CERS 0.09
- MACD
- GWRS -0.05
- CERS 0.01
- Stochastic Oscillator
- GWRS 38.42
- CERS 85.00
About GWRS Global Water Resources Inc.
Global Water Resources Inc operates as a water resources management company that owns, operates, and manages water, wastewater, and recycled water utilities in strategically located communities, principally in metropolitan Phoenix, Arizona. It operates within the State of Arizona.
About CERS Cerus Corporation
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.